Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 6;14(5):435.
doi: 10.3390/ph14050435.

Targeting Energy Expenditure-Drugs for Obesity Treatment

Affiliations
Review

Targeting Energy Expenditure-Drugs for Obesity Treatment

Carlos M Jimenez-Munoz et al. Pharmaceuticals (Basel). .

Abstract

Obesity and overweight are associated with lethal diseases. In this context, obese and overweight individuals infected by COVID-19 are at greater risk of dying. Obesity is treated by three main pharmaceutical approaches, namely suppressing appetite, reducing energy intake by impairing absorption, and increasing energy expenditure. Most compounds used for the latter were first envisaged for other medical uses. However, several candidates are now being developed explicitly for targeting obesity by increasing energy expenditure. This review analyzes the compounds that show anti-obesity activity exerted through the energy expenditure pathway. They are classified on the basis of their development status: FDA-approved, Withdrawn, Clinical Trials, and Under Development. The chemical nature, target, mechanisms of action, and description of the current stage of development are described for each one.

Keywords: FDA-approved; clinical trials; energy expenditure; energy metabolism; obesity; thermogenesis; treatments under development; withdrawn treatments.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Excess intake of calories causes overweight and obesity. There are three main pharmacological strategies to achieve a caloric deficit. Two of them aim to prevent the storage of excess calories, first by acting on the central nervous system to cause an anorexic effect and regulate appetite, and second by inducing early excretion and thus preventing ingested food from becoming a useful source of calories. The third strategy, and the topic of this review, is the use of drugs that increase energy expenditure by causing the body to use calories already stored in the form of fat.
Figure 2
Figure 2
Drugs, their targets, and their metabolic outcomes focusing on energy expenditure effect.
Figure 3
Figure 3
Chemical structures of drugs that increase energy expenditure that are approved by the FDA and withdrawn from the market.
Figure 4
Figure 4
Drugs that increase energy expenditure in clinical trials.
Figure 5
Figure 5
Drugs under development that increase energy expenditure.

References

    1. World Health Organisation Obesity and Overweight. [(accessed on 1 November 2019)]; Available online: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
    1. Blüher M. Obesity: Global epidemiology and pathogenesis. Nat. Rev. Endocrinol. 2019;15:288–298. doi: 10.1038/s41574-019-0176-8. - DOI - PubMed
    1. Popkin B.M., Du S., Green W.D., Beck M.A., Algaith T., Herbst C.H., Alsukait R.F., Alluhidan M., Alazemi N., Shekar M. Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. Obes. Rev. 2020;21:17. doi: 10.1111/obr.13128. - DOI - PMC - PubMed
    1. Wing R.R., Phelan S. Long-term weight loss maintenance. Am. J. Clin. Nutr. 2005;82:222S–225S. doi: 10.1093/ajcn/82.1.222S. - DOI - PubMed
    1. Tseng Y.-H., Cypess A.M., Kahn C.R. Cellular bioenergetics as a target for obesity therapy. Nat. Rev. Drug Discov. 2010;9:465–482. doi: 10.1038/nrd3138. - DOI - PMC - PubMed

LinkOut - more resources